• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 20, 2015

View Archived Issues

Pharma: In the clinic

Eli Lilly and Co., of Indianapolis, said it accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, and will extend the phase III trial of evacetrapib, a selective inhibitor of cholesteryl ester transfer protein, by approximately six months. Read More

In the clinic

Flex Pharma Inc., of Boston, said findings based on three randomized, blinded, placebo-controlled crossover trials in 37 healthy volunteers showed that leg cramps are caused by excessive firing of alpha-motor neurons in the spinal cord that control muscle contraction. Read More

Other news to note

Cerulean Pharma Inc., of Cambridge, Mass., said preclinical data for CRLX101, a tumor-targeted nanoparticle-drug conjugate designed to concentrate in tumors and slowly release anticancer payload camptothecin inside tumor cells, showed that, in an ovarian cancer model, CRLX101 monotherapy was highly efficacious, and chronic low-dose CRLX101 in combinaton with Avastin (bevacizumab, Roche AG) reduced hypoxia-inducible factor-1 alpha up-regulation and resulted in synergistic efficacy, with minimal toxicity in mice. Read More

Earnings

Pharmacyclics Inc., of Sunnyvale, Calif., disclosed results for the fourth quarter and for 2014, recording in the first full year of Imbruvica (ibrutinib) sales total revenue of $730 million, driven by U.S. net product revenue of $492 million for 2014, compared to U.S. net product revenue of $14 million for the prior year. Read More

Stock movers

Read More

Financings

Redhill Biopharma Ltd., of Tel Aviv, said underwriters of its public offering of 1 million American depository shares (ADSs) exercised in full their option to purchase 150,000 additional ADSs at $12.50 apiece as overallotments, extending total proceeds to approximately $14.4 million. Read More

FDA unveils preliminary agenda for NGS regs, but no talks yet with CMS

The FDA announced in a conference call this week that it is moving forward with development of a regulatory framework for next-generation gene sequencing systems, acknowledging at the outset that the task requires a substantially more streamlined approach than is currently available for in vitro diagnostics. Read More

Just 'ducky': Merganser lands $28M to advance peptides for iron overload

Named for a type of duck but definitely lacking any waddle in its step, Merganser Biotech Inc. made a big splash in the rare disease pond by reeling in a $28 million series A round led by the Novartis Venture Fund and joined by Frazier Healthcare, Sutter Hill Ventures and Osage University Partners. Read More

Blocking antioxidant pathways stops tumors in their tracks

Antioxidants seem to be on a Bill Cosby-like downward spiral from wholesomeness to villainy. The newest accusations can be found in the Feb. 9, 2015, issue of Cancer Cell, where scientists reported that antioxidants drove both the initiation and the progression of tumors, and that blocking antioxidant pathways could destroy tumor cells. Read More

Neurocrine prices $250M public offering; shares hold steady

Neurocrine Biosciences Inc., a San Diego company developing drugs for neurological and endocrine disorders, is banking $250 million in a public offering of about 6.9 million shares priced at $36 each to fund a growing roster of trials, rising R&D costs and plans to market its phase III tardive dyskinesia therapy, NBI-98854, ahead of an anticipated 2016 filing of its new drug application (NDA) for the movement disorder. Read More

EU's off-label use saga continues as industry files legal complaint

LONDON – The industry has escalated its campaign against European governments sanctioning off-label use of drugs in order to cut their pharmaceuticals bills, filing a legal complaint against a law passed in Italy in May 2014 that opened the way to use of products outside their approved indications. Read More

Appointments and advancements

Bellerophon Therapeutics Inc., of Hampton, N.J., appointed Deborah A. Quinn vice president and medical lead for the inopulse programs, and Martin Dekker vice president of device engineering. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe